Aldeyra Therapeutics, Inc. · NASDAQ:ALDX
Aldeyra Therapeutics — Investor Day (February 2020)
86 slides from Aldeyra Therapeutics's investor day presentation, Feb 24, 2020
Slide 1: A New Paradigm for the Treatment of Immune-Mediated Diseases
February 24, 2020 R&D Day 2020 A New Paradigm for the Treatment of Immune- Mediated Diseases Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements This presentation and various remarks which may be made during this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended
Slide 3: Value Proposition
Value Proposition Developing Next-Generation Medicines to Improve the Lives of Patients with Immune-Mediated Diseases DEEP AND INNOVATIVE PIPELINE 1 Focused on immune-mediated diseases NEAR-TERM DEVELOPMENT CATALYSTS 2 Late-stage trials in multiple indications VISION For our Drug SOLID TRACK RECORD
Slide 4: Three Late-Stage Ocular Programs Targeting Significant Unmet Needs
Three Late-Stage Ocular Programs Targeting Significant Unmet Needs Proliferative Dry Eye Disease Allergic Conjunctivitis Vitreoretinopathy Current Rx options can require Unchecked growing disease months to demonstrate even burden and limited options No approved therapy modest efficacy beyond OTC/Rx
Slide 5: Agenda
Agenda • Opening Remarks Todd Brady, M.D., Ph.D., President and CEO • Reproxalap in Dry Eye Disease David Clark, M.D., Chief Medical Officer • Reproxalap in Allergic Conjunctivitis Dr. Clark • Break • Ocular Surface Diseases Paul Karpecki, O.D., FAAO – Allergic Conjunctivitis and Dry Eye Disease • A
Slide 6: Reproxalap in Dry Eye Disease
February 24, 2020 David Clark, M.D., Chief Medical Officer Reproxalap in Dry Eye Disease Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020
Slide 7: Reproxalap Clinical Development in Dry Eye Disease
Reproxalap Clinical Development in Dry Eye Disease DRY EYE DISEASE PHASE 2a – Efficacy/safety of two concentrations (0.1%, 0.5%) RENEW-Part 1 – Two-part adaptive Phase 3; Efficacy/safety (0.25%) vs. vehicle DED symptoms Constant vs. induction/ 51 patients 4 weeks and signs 422 patients 12 weeks main
Slide 8: Reproxalap Met Dryness Symptom Primary Endpoint in RENEW-Part 1 and Formulation Phase 2
Reproxalap Met Dryness Symptom Primary Endpoint in RENEW-Part 1 and Formulation Phase 2 Clinical Trials Ocular Dryness Score (VAS) Change From Baseline Dryness (OD4SQ) Baseline Score > 3 RENEW-Part 1 Formulation Phase 2 (Induction-Maintenance Dosing) (Induction-Maintenance Dosing) Topical ocular rep
Slide 9: Relief of Dryness Generally Consistent Across Phase 2b, RENEW-Part 1, Formulation Phase 2
Relief of Dryness Generally Consistent Across Phase 2b, Both Dosing Arms of RENEW-Part 1, and Formulation Phase 2 Clinical Trials Ocular Dryness Score (OD4SQ) Change From Baseline Dryness (OD4SQ) Baseline Score > 3 Constant Dosing Induction-Maintenance Dosing RENEW- Phase 2b Part 1 RENEW- Formulatio
Slide 10: Combined Data from RENEW-Part 1 and Phase 2b: Rapid Symptom Control
Combined Data from Both Treatment Arms of RENEW-Part 1 and Phase 2b Clinical Trials Suggest Rapid and Potent Symptom Control Relative to Vehicle Ocular Dryness Score (OD4SQ) Change From Baseline Baseline Score > 3 • Mixed effect repeated measures analyzed over the two time points in common across bo
Slide 11: Staining Improvements Generally Consistent but Vehicle Effects Variable
Staining Improvements Generally Consistent but Vehicle Effects Variable Across Phase 2b and Both Treatment Arms of RENEW-Part 1 Clinical Trials Fluorescein Staining (Nasal Region) Change From Baseline Baseline Score > 2 Constant Dosing Induction-Maintenance Dosing RENEW- Phase 2b Part 1* RENEW- Form
Slide 12: Combined Data from RENEW-Part 1 and Phase 2b: Sign Control
Combined Data from Both Treatment Arms of RENEW-Part 1 and Phase 2b Clinical Trials Suggest Rapid and Potent Sign Control Relative to Vehicle Fluorescein Staining (Nasal Region) Change From Baseline Baseline Score > 2 • Mixed effect repeated measures analyzed over the two time points in common acros
Slide 13: Reproxalap in Dry Eye Disease
Reproxalap in Dry Eye Disease • Reproxalap has met the pre-specified symptom endpoint in RENEW-Part 1 and Formulation Phase 2 clinical trials. • Pooled data suggest early and potent activity vs. vehicle in dryness and staining. • Subsequent development plans are contingent on FDA feedback. 13
Slide 14: Reproxalap Drop Experience in Dry Eye Disease
February 24, 2020 David Clark, M.D., Chief Medical Officer Reproxalap Drop Experience in Dry Eye Disease Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020
Slide 15: Eye Drop Experience Study Evaluated Xiidra and Reproxalap Tolerability
Eye Drop Experience Study Evaluated Xiidra® and Reproxalap Instillation Tolerability Head-to-Head Conducted Q4 2019 • Objective: • Treatments: • Characterize the eye drop experience of • Reproxalap 0.25% (current formulation) reproxalap 0.25% compared to Xiidra® • Reproxalap 0.25% (alternate formula
Slide 16: Tolerability of Reproxalap Over One Hour Improved vs. Xiidra
Tolerability of Reproxalap Over One Hour Post-Instillation Significantly Improved vs. Xiidra® in Dry Eye Disease Patients Ocular Discomfort Rating Blurry Vision Rating Taste Dysgeusia Rating 4.5 4.5 4.5 Xiidra® Xiidra® Xiidra® Average Blurry Vision Rating (0-10) Score Average Ocular Discomfort Ratin
Slide 17: Reproxalap in Dry Eye Disease Q&A
February 24, 2020 David Clark, M.D., Chief Medical Officer Reproxalap in Dry Eye Disease Q&A Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020
Slide 18: Reproxalap in Allergic Conjunctivitis
February 24, 2020 David Clark, M.D., Chief Medical Officer Reproxalap in Allergic Conjunctivitis Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020
Slide 19: Reproxalap Clinical Development in Allergic Conjunctivitis
Reproxalap Clinical Development in Allergic Conjunctivitis ALLERGIC CONJUNCTIVITIS Conjunctival Allergen Allergen Field Study Challenge Efficacy/safety of two conc. PHASE 2a – Efficacy/safety (0.5%) vs. vehicle Allergen Field Study – (0.25%, 0.5%) vs. vehicle AC symptoms Field model methods 100 pati
Slide 20: Reproxalap Demonstrated Drug Effect Across Three Clinical Models of Allergic Conjunctivitis
Reproxalap Demonstrated Drug Effect Across Three Unique Clinical Models of Allergic Conjunctivitis Allergen Conjunctival Allergen Chamber Field Study Allergen Challenge Patients administer drug at home Investigator administers one drop Investigator monitors and assists during allergy season and main
Slide 21: Field Study: Allergic Itch Reduction on Highest Pollen Days
Field Study Illustrated Pollen-Variation Limitation of Clinical Model: Reproxalap Demonstrated Allergic Itch Reduction on Highest Pollen Days Allergen Field Study Histogram of Pollen Exposure During Field Study Ocular Itch (0-4) Change from Baseline on Highest Pollen Days* * Topical ocular reproxala
Slide 22: Durable Allergic Itch Reduction in Phase 3 Conjunctival Allergen Challenge
Reproxalap Demonstrated Durable Allergic Itch Reduction in Phase 3 Conjunctival Allergen Challenge Clinical Trial Conjunctival Allergen Challenge Total Ocular Itch Score (Area Under the Curve): Probability of Two-Point Response - Ocular Itching Score: 10 to 60 Minutes After Conjunctival Allergen Cha
Slide 23: Durable Itch and Redness Reduction in Allergen Chamber Model
Reproxalap Demonstrated Durable Allergic Ocular Itch and Redness Reduction in Allergen Chamber Clinical Model Allergen Chamber Ocular Itching Score: Ocular Redness Score: During 3.5 Hours of Allergen Exposure During 3.5 Hours of Allergen Exposure Topical ocular reproxalap has been studied in over 1,
Slide 24: The INVIGORATE Phase 3 Clinical Trial Design
The INVIGORATE Phase 3 Clinical Trial Design • Primary endpoint: • Statistical significance in ocular itch (0-4 scale) at a majority Two-Way Randomized Crossover of eleven time points between 110 and 210 minutes • Secondary endpoints: N≈60 N≈60 • Investigator-assessed ocular redness score • Patient-
Slide 25: Reproxalap in Allergic Conjunctivitis
Reproxalap in Allergic Conjunctivitis • Reproxalap has demonstrated robust drug activity in multiple allergic conjunctivitis clinical models. • Reproxalap allergic conjunctivitis clinical trial results to date demonstrate: • Rapid and durable onset of activity. • Clinically relevant improvements in
Slide 26: Ocular Itch Reduction Over Vehicle in Dry Eye Disease Patients in RENEW-Part 1
Reproxalap Demonstrated Statistically Significant Ocular Itch Reduction Over Vehicle in Dry Eye Disease Patients in RENEW-Part 1 DED Field Study Reproxalap has demonstrated CAC Ocular Itching Score Change From Baseline reduction in itch drug effect across four independent clinical models DRY EYE DIS
Slide 27: Reproxalap in Allergic Conjunctivitis Q&A
February 24, 2020 David Clark, M.D., Chief Medical Officer Reproxalap in Allergic Conjunctivitis Q&A Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020
Slide 28: Break
fee) aldeyra ‘ BREAK R&D Day 2020
Slide 29: Understanding Allergy and DED in the Landscape of Ocular Surface Diseases
Understanding Allergy and DED in the Landscape of Ocular Surface Diseases Paul M. Karpecki, OD, FAAO Director, Cornea Services, Kentucky Eye Institute, Gaddie Eye Associate Professor, KYCO Chief Medical Editor, Review of Optometry Medical Director, KEPLR Vision Practice Development Director, iOR Par
Slide 30: Ocular Surface Diseases
Ocular Surface Diseases • A number of very common conditions affecting the cornea, eyelids, and conjunctiva of the eye • The most common OSDs include: • Allergic conjunctivitis • Dry eye disease • Blepharitis 30
Slide 31: Allergies
Allergies • A systemic condition • An immune response to naturally occurring substances • Can be severe and life threatening – e.g. anaphylaxis 31
Slide 32: Incidence
Incidence • Up to 30% of the US population suffer from some form of allergy and increasing • Fonacier L, Luchs J, Udell I. Ocular Allergies Current Concepts in Allergy and Asthma 2001 Jul;1(4):389-96 • Allergies are the 6th leading cause of chronic disease in the US • Bielory L. Ocular allergy guide
Slide 33: Prevalence in Children
Prevalence in Children • Up to 40% of children! • Allergic conjunctivitis is the most common ocular allergy syndrome among children • More serious allergic eye diseases less common, but more devastating if not caught or treated early • Average age of symptoms of DED ~ 26 Abelson MB, Granet D. Ocular
Slide 34: Prevalence is Increasing
Prevalence is Increasing • Due to numerous factors and theories: • Hygiene theory • Climate change • Genetics • Studies have shown that if both parents suffer from allergies, the child has a 65% chance of developing them 34
Slide 35: Impact on Daily Activities
Impact on Daily Activities Assessed by the Eye Allergy Patient Impact Questionnaire 73% N = 124 70% Percent of Patients (%) 61% 58% 55% 45% Going Outdoors Reading Driving Concentrating Sleeping Putting on/ on Daily Tasks Wearing Make-up 35 Lorenz et al. J Outcomes Res. 2003;7:21.
Slide 36: Allergic Eye Diseases
Allergic Eye Diseases • Seasonal allergic conjunctivitis (SAC) • Atopic keratoconjunctivitis (AKC) • Vernal keratoconjunctivitis (VKC) • Giant Papillary conjunctivitis (GPC) • Perennial allergic conjunctivitis (PAC) • All Type I hypersensitivity reactions 36
Slide 37: Normal
Normal Presenting patient Asymptomatic # TFOS DEWS lt Pathophysiology / Tear Film / Diagnosis No signs Signs of Ocular Surface Disease Signs of Ocular Surface Disease {f Triaging questions #TFOS DEWS lt Diagnosis Other Ocular Symptoms Surface Disease: without signs: Differential Diagnoses pre-clinic
Slide 38: Diagnostic Methodology
severe smoking, certain medications, contact lens wear Diagnostic Tests IGS Non-invasive [fluorescein] Tear Breakup (1) Ica Risk ‘Symptomology § (DEQ-5 =6 Factor ADEO-Di= Analysis OsDI = 13) Triaging Questions t Evaporative Spectrum Class’ Ocular Surface Staining > 5 comeal spots, > 9 conjunctival ‘
Slide 39: Slide 39
Slide 40: Slide 40
Slide 41: Most Common DED Treatments
Most Common DED Treatments • Eliminate exacerbating factors – smoking, air conditioner, meds. • Tear replacements/ATs • Warm compresses, lid hygiene, nutrition • But none of these slow progression or treat the disease/inflammation
Slide 42: DED Treatments by Cause
OBSTRUCTION BIOFILM INFLAMMATION TEAR FILM • Blink exercises • Blepharoexfoliation • Lifitegrast (Xiidra) • Artificial tears • Moist heat compress (Blephex) • Cyclosporine • Environment changes (Bruder) • Hypochlorous acid (Restasis/Cequa) • Increase hydration • Lid debridement • Tea tree oil • Cort
Slide 43: DED Inflammation and Tear Volume Treatments
INFLAMMATION TEAR VOLUME • Artificial tears • Lifitegrast (Xiidra) • Environment changes • Cyclosporine (Restasis) • Increase hydration • Corticosteroids • Punctal occlusion • Omega fatty acids • Neurostimulation • PO Doxycycline • Cevimeline PO (Evoxac) • PO Azithromycin • Autologous serum q2h • Am
Slide 44: Most Significant Challenges for ECPs in Treating Ocular Allergies
Most Significant Challenges for ECPs in Treating Ocular Allergies • Managing co-morbidity of dry eye with AC • Maintaining patients in contact lenses – Oral antihistamines dry the eyes – Dry eye patients can’t wash away the allergens on the ocular surface – Welch D, Ousler GW, Nally LA et al. Ocular
Slide 45: Oral OTC Allergy Meds
Oral OTC Allergy Meds • Most patients (>80%) seek OTC options prior to visiting a doctor’s office • Primary treatment is oral anti-histamines • Can exacerbate the ocular condition • Incidence of dry eye ~14.4% Beaver Dam study data – over age 40 BOSS Study Paulsen age 21 and older 45
Slide 46: Dry Eye and Allergy
Dry Eye and Allergy • Need adequate tears to wash away allergens • M3 Muscarinic receptor effects of oral antihistamines – 50% reduction in tear production (M. Abelson) – Loratadine 34% reduction in tear volume after 4 days (Ousler) • Compounding effects 46
Slide 47: Dry Eye and Allergy
Dry Eye and Allergy • Difficult to separate the two • E.g. symptoms of tearing, burning, grittiness, stinging eyes • More common to see the vague symptoms • Signs of inflammation are similar regardless of disease cause 47
Slide 48: Hom Study Summary
Hom Study Summary • AC and DED are two of the most common OSD disorders • N=689, patient age range 5-90 (median age 25) • 28.2% had itchiness • 35.8% dry eyes • 28.2% redness 48
Slide 49: Hom Study Summary
Hom Study Summary • Of the 194 patients (28.2%) with itching, 57.7% had clinically significant dryness • Of the 247 patients with dry eyes, 112 (44.3%) had clinically significant itch • The odds of a patient with itching eyes experiencing dry eyes was 2.11 times and the odds of these patients also e
Slide 50: Hom Study: AC and DED Clinically Manifest Similar Symptoms
Hom Study: AC and DED Clinically Manifest Similar Symptoms and Readily Mimic Each Other Allergic Conjunctivitis and Dry Eye Disease Relationship Among Subgroups Patients with a history of AC (n=689) screened for clinically significant itching, dryness, and redness. 14% Itch 11% Dryness Total No. (%)
Slide 51: Opitz Conference Paper: Ocular Surface Disease Patients Often Have DED and AC Co-Morbidity
Opitz Conference Paper: Ocular Surface Disease Patients Often Have DED and AC Co-Morbidity Prevalence of Co-Morbid Ocular Surface Diseases Mixed Combination of Conditions Ocular surface disease patients (n=258) were classified into evaporative dry eye, aqueous tear deficient dry eye, Mixed diseases
Slide 52: Allergic Conjunctivitis and Dry Eye Disease Are Interrelated
Allergic Conjunctivitis and Dry Eye Disease Are Interrelated Inflammatory Ocular Surface Diseases The Three P’s of Ocular Surface Inflammation: Parched Pollens Pollutants Environments Allergic Dry Eye Conjunctivitis Disease • Allergic response can compromise tear film “The clear interaction of aller
Slide 53: Types of Allergic Eye Disease
Types of Allergic Eye Disease 53
Slide 54: Seasonal vs. Perennial Allergic Conjunctivitis
Seasonal vs. Perennial Allergic Conjunctivitis • Allergens seasonally present – Tree, grass, weed pollens • Allergens always present – Animal dander – Dust mites – Molds 54
Slide 55: Allergic Conjunctivitis
Allergic Conjunctivitis Perennial Allergic • Milder than seasonal allergy ➢ Associated with asthma Conjunctivitis ➢ Year round problem & indoors ➢ High pollen counts • 70-80% allergic to dust mite droppings: ➢ Mites are 10-24µ ➢ 10-20 waste pellets/day ➢ 1 gram dust = 240,000 droppings 55
Slide 56: Acute Allergic Conjunctivitis or Seasonal Allergic Conjunctivitis
Acute Allergic Conjunctivitis or Seasonal Allergic Conjunctivitis • Ragweed, pollen, mold • Higher incidence at certain times of the year • Perennial allergic conjunctivitis (PAC) – All year – e.g. animal dander, dust, – Indoor allergies 56
Slide 57: Acute Allergic Conjunctivitis
Acute Allergic Conjunctivitis Seasonal Allergic • Environmental allergens ➢ Animal Dander Conjunctivitis ➢ Ragweed ➢ Grass Pollen 57
Slide 58: SAC Treatment
SAC Treatment • Palliative Recommendations: – Preservative free tears – Cool compresses 58
Slide 59: Acute Allergic Conjunctivitis
Acute Allergic Conjunctivitis Signs ➢Hyperemia ➢Chemosis ➢Mucous Discharge ➢Lid Edema 59
Slide 60: 60
60
Slide 61: Clinical Presentation
Clinical Presentation Symptoms: • Ocular itching • Sensitivity to light • Burning • Grittiness/foreign-body • Tearing sensation • Redness • Blurred vision 61
Slide 62: The Early (Acute) Allergic Response
The Early (Acute) Allergic Response Antigen in tears Conjunctival epithelium Histamine ECF-A Blood Vessel Heparin Chymase Tryptase Synthesis Leukotrienes Prostaglandins Eosinophil Cytokines Basophil Activated mast cell Platelet Activating Factor Adapted with permission from Lichtenstein LM. Allergy
Slide 63: SAC Symptoms (Itch)
SAC Symptoms (Itch) • Antihistamine/mast cell stabilizer combination drops • Better on symptoms but no indication for signs 63
Slide 64: SAC Signs
SAC Signs • Moderate to severe erythema and edema • Steroid drops • Slower acting but better on signs (redness and chemosis/swelling) 64
Slide 65: The Late Phase Allergic Response
The Late Phase Allergic Response Blood Leukotrienes Vessel Cytokines Eosinophil Activated mast cell Prostaglandins Basophil Lipids Chemokines Histamine Cytokines Adapted with permission from Lichtenstein LM. Allergy and the immune system. Scientific Am. 1993;269:117-124. 65
Slide 66: Need for a New Therapy
Need for a New Therapy • One that acts on signs and symptoms • Works like a steroid without the long- term risks and side effects • One that won’t add to the dry eye co- morbidity 66
Slide 67: Optometry at the Front Line
Optometry at the Front Line • 88% of all comprehensive eye exams • 431 graduating ophthalmology residents- essentially the same over 30 years • 76 million baby boomers needing cataract surgery • Estimates for FTE’s required: ~24,000 MDs • Currently there are only ~ 18,000 MDs • 40,000 ODs 67
Slide 68: Need for Versatile Therapeutics to Treat Inflammation
Need for Versatile Therapeutics to Treat Inflammation • The one consistent component of all OSD’s is inflammation • Corticosteroids have limitations • Short term therapy/flare ups and these OSDs are chronic conditions • IOP rise, PSC cataracts, secondary infections if used long-term • Potential for
Slide 69: Need for Versatile Therapeutics to Treat Inflammation
Need for Versatile Therapeutics to Treat Inflammation • Doctors have difficulty differentiating DED from AC (and blepharitis) • Co-morbidities are very large making it more difficult • Need for a single drug class that can safely and effectively treat the inflammation, regardless of the type of OSD
Slide 70: Reproxalap's Novel Mechanism of Action Differentiated Versus Antihistamines
Reproxalap’s Novel Mechanism of Action Has The Potential to Provide Differentiated Activity Versus Antihistamines Histaminic Phase Post-Histaminic Phase (minutes) (builds over hours) Reproxalap • Reproxalap irreversibly inhibits Cell activation RASP, limiting allergic inflammation. RASP • Reproxalap
Slide 71: What may I answer?
What may I answer? 71
Slide 72: Allergic Conjunctivitis Market Opportunity
February 24, 2020 David McMullin, Chief Commercial Officer Allergic Conjunctivitis Market Opportunity Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020
Slide 73: Allergy Season: A Timeline
Allergy Season: A Timeline ‘The Pollenpocalypse Is ‘Pollen Tsunami’ Causing Why allergy sufferers Coming. Here's What to Do Misery in the Northeast have months of misery When It Strikes. Now a ‘Pollen Vortex’? ‘Get the Kleenex ready’: Tree Wild Weather May Mean Why this spring is a perfect pollen is
Slide 74: Allergy Seasons Are Getting Longer, Broader, and Denser
Allergy Seasons Are Getting Longer, Broader, and Denser A Trend Likely to Persist for Decades to Come Longer Broader Denser Change in Ragweed Pollen Season Projected Change in Ragweed Ragweed Pollen Production by Year3 Length: 1995-20151 Distribution by 20502 25 Pollen production (grams per plan) Ch
Slide 75: Growing Burden of Pollen Related Allergies is a Global Phenomenon
Growing Burden of Pollen Related Allergies is a Global Phenomenon Changes in Pollen Load and Season Duration Across The Northern Hemisphere Over The Last 20+ Years1 71% of studied locations showed significant 14 increases in seasonal pollen concentration USA, Fairbanks 12 USA, Minneapolis % Change i
Slide 76: Seasonal Allergy Patients Are Feeling The Impact
Seasonal Allergy Patients Are Feeling The Impact Source: “Grass pollen season tough on those with allergies, asthma” by Jack Moran in The Register-Guard; May 2018. 76 Respiratory therapist talks about asthma and pollen at PeaceHealth Sacred Heart Medical Center.
Slide 77: Record Levels of Consumers Are Searching for Allergy Information
Record Levels of Consumers Are Searching for Information on (and Solutions to) Allergies and Pollen Every Year Changes in Search Term Trends in the United States Over The Last 10 Years Search Term “Allergies” Search Term “Pollen” 100 100 90 90 80 80 70 70 Relative Search Interest 60 60 Relative Sear
Slide 78: Allergic Conjunctivitis Prescription Volume Has Grown 3x Faster Than Population
Allergic Conjunctivitis Prescription Volume Has Grown 3x Faster Than the General Population Over the Past Ten Years Allergic Conjunctivitis Patient Journey Allergic Conjunctivitis Total Prescriptions (TRx) United States TRx Demand Outpacing 10.0 Population Growth Self-Diagnosis and Treatment 9.6 Tot
Slide 79: Allergic Conjunctivitis Treatment Landscape Has Been Stagnant
The Allergic Conjunctivitis Treatment Landscape Has Been Stagnant With No Novel Drug Entrant in Decades Allergic Conjunctivitis Eye Drop Drug Class: Vasoconstrictors Antihistamines Mast Cell Stabilizers NSAIDs Corticosteroids (Decongestants) First 1950s 1950s – 1st generation 1980s Late 1990s Late 1
Slide 80: Some AC Patients Utilize Multiple Rx Treatments
Some Allergic Conjunctivitis Patients Utilize Multiple Rx Treatments, and Nearly 1 in 4 Use Current Non-Antihistamine Rx Alternatives 1 in 10 1 in 4 1 in 10 diagnosed Nearly 1 in 4 of allergic conjunctivitis diagnosed allergic patients are being conjunctivitis prescribed more patients are using than
Slide 81: Reproxalap Has the Potential to Be the First Novel Drug in Decades
Reproxalap Has the Potential to Be the First Novel Drug For Allergic Conjunctivitis in Decades, Representing A Unique Market Opportunity Likelihood of Trying % of AC Patients Where Reproxalap a Novel MOA for Where Reproxalap Fits Into the Allergic Conjunctivitis Could Be Prescribed AC Treatment Algo
Slide 82: Allergic Conjunctivitis Market Opportunity Q&A
February 24, 2020 David McMullin, Chief Commercial Officer Allergic Conjunctivitis Market Opportunity Q&A Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020
Slide 83: Proliferative Vitreoretinopathy Patient Video
February 24, 2020 Todd Brady, M.D., President and CEO Proliferative Vitreoretinopathy Patient Video Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020
Slide 84: Concluding Remarks
February 24, 2020 Todd Brady, M.D., President and CEO Concluding Remarks Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020
Slide 85: Our Lead Programs Represent Compelling Commercial Opportunities
Our Lead Programs Represent Compelling Commercial Opportunities Proliferative Dry Eye Disease Allergic Conjunctivitis Vitreoretinopathy Reproxalap 0.25% Reproxalap 0.25% ADX-2191 Early and consistent symptom Clinically significant and Potential therapeutic and sign improvements in durable symptom re
Slide 86: A New Paradigm for the Treatment of Immune-Mediated Diseases
A New Paradigm for the Treatment of Immune- Mediated Diseases Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2020